The purpose of this study is to investigate the effect of combined glucagon-like-peptide-1
(GLP-1) analogue and metformin therapy on glucose metabolic and cardiovascular endpoints
compared to metformin monotherapy in patients with coronary artery disease (CAD) and newly
diagnosed type 2 diabetes (T2D).
It is hypothesized that GLP-1 analogue added to backbone therapy of metformin in CAD patients
with T2D will improve beta-cell function, left ventricular ejection fraction (LVEF), heart
rate variability and lower 24h blood pressure among other selected endpoints.
The present study on CAD patients with newly diagnosed T2D will address these selected
endpoints during an investigator initiated, randomized, double blind, crossover,
placebo-controlled 12 + 12 weeks intervention study with a 2 week wash-out period.